Clinical Trial Search

Primary: Glucose Tolerance at 24 Weeks — 2; 4; 3; 4 Participants

Primary: Dose Limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change

Primary: Change in Prostaglandin E2 (PGE2) Concentrations — -457.7; -840.4 pg/ml

Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL

Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants

Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001

Primary: VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. — 5.71; 6.04; 4.92; 4.87 units on a scale — p=.25

Primary: Change of Coefficient of Fat Absorption (CFA) (%) Between Baseline and End of Double-blind (DB) Period. — 31.93; 8.72 Percentage — p=<0.0001

Primary: Change in Peak Bicarbonate Concentration, Measured Using Endoscopic Pancreatic Function Test (ePFT) — -8.20; 5.50 mmol/l

Primary: The T2* Values in the Diagnosis of AP — 25.86; 21.06 ms — p=<0.01

Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min

Primary: Exploratory: Percentage Change in IL-2 Production Relative to Pre-dose Values — -55.5 percentage of change in IL-2 production

Primary: Number of Patients With Adverse Drug Reaction — 36 participants

Primary: EUS Pancreatic Findings- Rosemont Criteria — 36; 0; 26; 0 percentage of participants

Primary: Pain (Visual Analog Scale, CGI, PGA) — 7; 0 number of participants w/ reduced pain

Primary: Change in C-reactive Protein (C-RP) From Admission Baseline at One Week. — 86.2; 75.8; 116.4; 127.2 mg/L — p=0.5796

Primary: Change in C-Reactive Protein (CRP) — 48.4; 60.6; 62; 154 mg/L — p=0.62

Primary: Islet Graft Function — 233; 354 ng/ml*min

Primary: Change in Adolescent Abdominal Pain Severity — 2.11; 1.74; 1.99; 1.61 scores on a scale

Primary: Mean Change in Total Symptom Score (TSS) From Day 1 (Baseline) to Days 8, 15, 29, and 85 — 0.0012; 0.0480; 0.1506; 0.0791 score on a scale

Primary: Pain Reduction — 12 Participants — p=0.999

Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants

Primary: Proportion of Approached Individuals Who Met Eligibility Criteria — 12 Participants

Primary: The Safety and Tolerability of CM4620-IE in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS) or Hypoxemia. — 7; 5; 3; 0…

Primary: Decreased Secretions — 1 participants

Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804

Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43

Primary: Change in Pain Response Over a 6 Month Period of Time Using the VAS Score

Primary: S-MRCP and S-EUS Concordance